| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.019 | 0.7 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | 0.027 | 0.7 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |